"# Greig NH, Ruckle J, Comer P, Brownell L, Holloway HW, Flanagan DR Jr, Canfield CJ, Burford RG: Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. Curr Alzheimer Res. 2005 Oct;2(4):483-92. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16248851 # Klein J: Phenserine. Expert Opin Investig Drugs. 2007 Jul;16(7):1087-97. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17594192 # Thatte U: Phenserine (Axonyx/NIH). IDrugs. 2000 Oct;3(10):1222-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16049844"@en . . . "Rapidly absorbed and cleared from the body."@en . "Humans and other mammals"@en . "(-)-phenserine"@en . . . "investigational"@en . . . . . . "101246-66-6"@en . . . "Phenserine"@en . . . . . . "Phenserine is under development by Axonyx, a US biopharmaceutical company that focuses on treatments for dementia. Phenserine is a next generation acetylcholinesterase (AChE) inhibitor indicated for the treatment of AD. Unlike currently marketed AChE inhibitors, it has a dual mechanism of action that also includes anti-amyloid activity, which may confer disease-modifying effects in patients with AD. If this is substantiated in an ongoing clinical trial then phenserine may open the door to an entirely new type of treatment for AD. Axonyx announced on 20 September 2005 that phenserine was ineffective in two curtailed phase 3 trials."@en . . . . . . "For the treatment of Alzheimer's disease (AD)."@en . "8 to 10 hours"@en . . . . . . . . "Phenserine is a highly selective, reversible acetylcholinesterase inhibitor, a mechanism of action known to improve memory and cognition in Alzheimer\u2019s subjects. Phenserine may prove to concentrate in the brain rapidly which would reduce the incidence of drug toxicity and side effects."@en . . . . . "The toxicity of phenserine, a derivate of physostigmine, is dramatically less. Doses of 20 mg/kg (rats, intravenous) of phenserine have not been associated with toxicity or deaths."@en . . "(-)-eseroline phenylcarbamate"@en . .